Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1217032.RAZ9bDN3j31mXQztKQJHBz-4-AoOrAQwMUNpCLgF4aSDQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1217032.RAZ9bDN3j31mXQztKQJHBz-4-AoOrAQwMUNpCLgF4aSDQ130_assertion type Assertion NP1217032.RAZ9bDN3j31mXQztKQJHBz-4-AoOrAQwMUNpCLgF4aSDQ130_head.
- NP1217032.RAZ9bDN3j31mXQztKQJHBz-4-AoOrAQwMUNpCLgF4aSDQ130_assertion description "[Several randomized trials have shown that the use of mTOR inhibitors could improve patient outcome with hormone receptor-positive or human epidermal growth factor receptor-2-positive breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217032.RAZ9bDN3j31mXQztKQJHBz-4-AoOrAQwMUNpCLgF4aSDQ130_provenance.
- NP1217032.RAZ9bDN3j31mXQztKQJHBz-4-AoOrAQwMUNpCLgF4aSDQ130_assertion evidence source_evidence_literature NP1217032.RAZ9bDN3j31mXQztKQJHBz-4-AoOrAQwMUNpCLgF4aSDQ130_provenance.
- NP1217032.RAZ9bDN3j31mXQztKQJHBz-4-AoOrAQwMUNpCLgF4aSDQ130_assertion SIO_000772 25189767 NP1217032.RAZ9bDN3j31mXQztKQJHBz-4-AoOrAQwMUNpCLgF4aSDQ130_provenance.
- NP1217032.RAZ9bDN3j31mXQztKQJHBz-4-AoOrAQwMUNpCLgF4aSDQ130_assertion wasDerivedFrom befree-2016 NP1217032.RAZ9bDN3j31mXQztKQJHBz-4-AoOrAQwMUNpCLgF4aSDQ130_provenance.
- NP1217032.RAZ9bDN3j31mXQztKQJHBz-4-AoOrAQwMUNpCLgF4aSDQ130_assertion wasGeneratedBy ECO_0000203 NP1217032.RAZ9bDN3j31mXQztKQJHBz-4-AoOrAQwMUNpCLgF4aSDQ130_provenance.